Accessibility Menu
Arrow-Thin-Down
S&P 500
6,800.22
+0.9%
+61.78
Arrow-Thin-Down
DJI
47,237.62
+1.1%
+503.01
Arrow-Thin-Down
NASDAQ
23,227.27
+1.2%
+285.47
Arrow-Thin-Down
Bitcoin
$110,265.00
+0.3%
+$287.17
Arrow-Thin-Down
AAPL
$263.30
+1.4%
+$3.72
Arrow-Thin-Down
AMZN
$224.78
+1.7%
+$3.69
Arrow-Thin-Down
GOOG
$261.86
+3.2%
+$8.13
Arrow-Thin-Down
META
$737.14
+0.4%
+$3.14
Arrow-Thin-Down
MSFT
$523.36
+0.5%
+$2.80
Arrow-Thin-Down
NVDA
$184.94
+1.5%
+$2.78
Arrow-Thin-Down
TSLA
$435.11
-3.1%
-$13.87
Daily Stock GainersDaily Stock LosersMost Active Stocks
Coya Therapeutics Stock Quote

Coya Therapeutics (NASDAQ: COYA)

$6.68
(-4.3%)
-0.30
Price as of October 24, 2025, 1:08 p.m. ET

KEY DATA POINTS

Current Price
$6.68
Daily Change
(-4.3%) $0.30
Day's Range
$6.07 - $6.80
Previous Close
$6.98
Open
$6.60
Beta
1.19
Volume
923,766
Average Volume
120,300
Sector
Health Care
Market Cap
116.7M
Market Cap / Employee
$6.98M
52wk Range
$4.65 - $10.24
Revenue
-
Gross Margin
0.94%
Dividend Yield
N/A
EPS
-$1.24
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Coya Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
COYA-28.04%N/AN/A+53%
S&P+16.23%+94.45%+14.22%+75%

Coya Therapeutics Company Info

Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Financial Health

General

Q2 2025YOY Change
Revenue$0.16M-95.2%
Gross Profit$0.16M-95.4%
Gross Margin95.82%-4.0%
Market Cap$96.17M4.3%
Market Cap / Employee$12.02M0.0%
Employees80.0%
Net Income-$6.09M-110.8%
EBITDA-$6.41M-98.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$29.76M-18.6%
Accounts Receivable$0.00M-100.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-55.43%-18.3%
Return On Invested Capital-94.18%14.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$5.77M-26.5%
Operating Free Cash Flow-$5.77M-26.5%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book2.782.722.732.885.90%
Price to Sales10.2826.9429.36227.112300.64%
Price to Tangible Book Value2.782.722.732.885.90%
Enterprise Value to EBITDA-15.11-14.09-9.47-10.36-37.80%
Return on Equity-50.8%-39.6%-52.0%-64.0%53.67%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services